

SUBJECT INDEX

- A32187, 538P
 Absorption, 307P, 550P, 699P
 Acetylcholine, 15P, 112P, 193P, 284P, 531P, 658P
 Acetylcholine receptors, 432P, 457P
 Acetylcholine release, 471P, 472P, 717P
 Acetylcholine synthesis, 244P
 Acetylcholinesterase, 639P
 N-acetylhistamine, 641P
 3-Acetylpyridine, 94P
 α_1 -acid glycoprotein, 376P
 Action potentials, 121P
 Acute phase proteins, 54P
 Adenosine, 150P, 256P, 368P, 385P, 471P, 643P
 Adenosine, deaminase, 382P
 Adenosine dependence, 176P
 Adenosine diphosphate, 159P
 Adenosine 3',5';monophosphate, cyclic, 184P, 348P, 361P, 519P, 544P, 606P
 Adenosine 3',5';monophosphate, dibutyr-yl cyclic, 78P
 Adenosine nucleotides, 498P
 Adenosine A₁ receptor, 176P
 Adenosine A₂ receptor, 256P
 Adenosine triphosphatase, 419P
 Adenosine triphosphate, 364P
 Adenylate cyclase, 158P, 375P, 605P, 654P, 686P
 Adenylate cyclase, postsynaptic dopa-mine-sensitive, 646P
 Adipose tissue, 231P
 Adipose tissue, brown, 303P, 397P
 Adrenal gland, rats, 75P
 Adrenal imaging agent, 707P
 Adrenalectomy, 251P
 Adrenaline, 157P, 318P
 Adrenergic blockade, 491P
 Adrenergic neurone blockers, 386P
 β -Adrenoceptor affinities, 383P
 Adrenoceptor agonists, 452P
 α -Adrenoceptor agonists, 196P, 474P
 α_2 -Adrenoceptor agonists, 110P
 Adrenoceptor antagonists, 680P
 α_1 -Adrenoceptor antagonists, 388P
 α_2 -Adrenoceptor antagonists, 109P, 110P, 151P, 308P, 309P, 311P, 312P, 314P, 462P, 665P
 β -Adrenoceptor antagonists, 24P, 34P, 111P, 152P, 153P, 609P, 698P
 β_1 -Adrenoceptor antagonists, 183P, 235P
 β_2 -Adrenoceptor antagonists, 233P
 α_1 -Adrenoceptor behaviour, 372P
 Adrenoceptor binding, 536P
 β -Adrenoceptor binding, 686P
 β -Adrenoceptor localisation, 520P
 Adrenoceptor mechanism, 175P
 Adrenoceptor modulation, 467P
 Adrenoceptors, 106P, 140P, 157P, 158P, 517P, 619P, 651P
 Adrenoceptors, vascular, 205P
 α -Adrenoceptors, 10P, 45P, 73P, 130P, 227P, 229P, 236P, 300P, 307P, 310P, 458P, 460P, 465P, 572P, 614P, 615P, 617P, 672P, 681P
 α -Adrenoceptors, postjunctional, 44P
 α -Adrenoceptors, presynaptic, 43P, 510P
 α_1 -Adrenoceptors, 108P, 156P, 461P, 475P, 480P, 578P
 α_{1S} -Adrenoceptor, 155P
 α_2 -Adrenoceptors, 37P, 40P, 41P, 42P, 74P, 128P, 146P, 151P, 190P, 228P, 234P, 305P, 311P, 312P, 313P, 504P, 521P, 542P, 616P
 α_2 -Adrenoceptors, intra- and extrasynap-tic, 477P
 α_2 -Adrenoceptors, postjunctional, 69P, 134P
 α_2 -Adrenoceptors, postsynaptic, 147P, 225P
 α_2 -Adrenoceptors, presynaptic, 27P, 225P, 464P
 α_2 -Adrenoceptors, smooth muscle, 230P
 β -Adrenoceptors, 72P, 107P, 141P, 231P, 254P, 375P, 508P, 618P
 β -Adrenoceptors, cardiac, 136P
 β -Adrenoceptors, presynaptic, 509P, 620P
 ADTN, 645P
 (³H) ADTN binding, 403P
 Aflatoxin B₁, 61P
 Age, 116P, 246P, 464P, 672P
 Aggregation, 521P
 Airway hyperreactivity, 599P
 Airway preparations, 215P
 Airway sensitivity, 153P
 Airway smooth muscle, 330P, 446P, 503P, 598P
 Airways, cat, 253P
 Alcohol, 640P
 Alcoholic cirrhosis, 580P
 Aldose reductase, 248P
 Aldosterone, 695P
 Aldrin epoxidase, 712P
 Alinidine, 168P
 Allergy, 340P
 Alzheimer's disease, 287P
 Amaranth, 329P

Ambroxol, 693P
 Amiloride, 204P, 481P, 501P
 Amine release, 228P
 Amine uptake inhibitors, 20P, 21P
 Amino acids, endogenous, 527P
 DL-2-amino-4-phosphonobutyrate, 201P, 543P
 2-Amino-7-phosphonoheptanoic acid, 113P, 285P, 433P
 γ -Aminobutyric acid, 19P, 77P, 90P, 173P, 265P, 266P, 279P, 281P, 393P, 524P, 630P
 γ -Aminobutyric acid binding, 431P
 γ -Aminobutyric acid function, 278P
 γ -Aminobutyric acid mimetics, 658P
 γ -Aminobutyric acid receptors, 89P, 268P, 283P, 432P, 532P
 γ -Aminobutyric acid A receptors, 277P
 γ -Aminobutyric acid B receptors, 6P, 189P, 277P
 γ -Aminobutyric acid B sites, 644P
 γ -Aminobutyric acid uptake, 88P, 267P
 δ -Aminolaevulinic acid synthase, 448P
 6-Aminonicotinamide, 94P
 Aminooxyacetic acid, 507P
 Aminophenones, 326P
 Aminophosphonovaleric acid, 113P
 Aminophyllines, 335P
 Amphetamine, 11P, 93P, 449P, 455P, 719P
 Amphotericine B, 335P
 Anabesine, 272P
 Anaesthetics, 178P
 Anaesthetics, local, 421P
 Anal sphincter, 238P
 Analgesia, 47P, 188P, 191P, 247P, 489P, 633P
 Anaphylaxis, 440P
 Androgen receptor, 327P
 Anethole, *trans*, metabolism, 212P
 Angiotensin, 387P, 528P
¹²⁵I-angiotensin binding, 322P
 Angiotensin converting enzyme, 39P, 323P, 324P
 Anococcygeus muscle, 148P, 150P, 379P
 Anococcygeus muscle, mouse, 71P, 363P
 Anococcygeus muscle, rat, 227P, 301P
 Antiallergic agents, 58P, 374P
 Antiarrhythmic drugs, 203P, 368P
 Antibiotics, 699P
 Anticholinergic activity, 395P
 Anticholinesterase activity, 501P
 Anticoagulants, 339P
 Anticonflict activity, 265P
 Anticonvulsants, 113P, 278P, 283P, 484P, 627P
 Antidepressants, 41P, 372P, 539P, 560P, 662P, 665P
 Antidepressants, chronic treatment, 297P
 Antihaemolytic action, 498P
 Antihypertensive agents, 34P, 386P, 612P
 Anti-inflammatory drugs, 78P, 163P, 220P, 222P, 348P, 354P, 565P
 Antimicrobial agents, 596P
 Antinociception, 18P, 518P
 Antinociceptive agents, 572P
 Antipurinic agents, 567P
 Antipyrene clearance, 479P
 Anti secretory agents, 419P
 Anti-thrombotic drugs, 360P
 Anxiety, 286P, 653P
 Aorta, guinea-pig, 256P, 475P
 Aorta, rat, 50P, 445P, 475P, 578P
 Apamin, 546P
 Apomorphine, 429P, 473P, 549P, 561P, 650P
 AR-L 115 BS, 506P
 Arachidonic acid, 221P, 342P, 601P, 713P
 Arcuate neurones, 642P
 Arginine vasopressin, 436P, 690P
 Arrhythmias, 31P, 121P, 122P, 126P, 621P, 628P
 Arterial hyper-reactivity, 702P
 Artery, rat tail, 44P
 Arthritis, 691P
 Arthus, reactions, 417P
 Ascorbic acid, 195P, 402P, 403P, 536P
 Asparaginase, 336P
 Aspartate, 285P
 Aspartate release 2P
 Asthma, 340P
 Asymmetric circling behaviour, 399P
 Atenolol, 483P
 Atracurium, 704P
 Atria, guinea-pig, 706P
 Atria, human, 620P
 Atria, rat, 89P
 Atropine, 112P
 Attack, 347P
 Audiogenic seizures, 405P
 Automation, 185P
 Autoradiography, 280P, 520P, 644P, 656P
 Autoreceptor, 647P, 673P
 Avermectin, 524P
 Axonal transport, 248P, 366P
 Azathioprine, 492P
 Baclofen, 6P, 89P, 278P
 Barbiturate dependence, 291P
 Barbiturates, 659P
 Barium, 505P
 Baroreceptor reflexes, 434P
 Basal ganglia, 658P
 Basal ganglia, rat, 315P
 Base exchange, 537P

Basilar artery, human, 164P
 BDF 6143, 151P
 Behaviour, 10P, 97P, 394P, 636P
 Behavioural supersensitivity, 411P
 Benextramine, 562P
 Benoxaprofen, 55P
 Benzo(α)pyrene hydroxylase, 712P
 Benzodiazepine antagonists, 637P
 Benzodiazepine binding, 290P, 431P
 Benzodiazepine receptor, 77P, 288P
 Benzodiazepines, 94P, 95P, 281P, 294P, 487P, 530P, 557P, 630P, 653P
 Benzoic acid, 62P
 Benzold-Jarish reflex, 570P
 Benzomorphans, 412P
 Benzylamine, 301P
 Bepridil, 33P, 609P
 Bias, 714P
 Bicarbonate, 268P
 Bile, 329P, 563P
 Biliary metabolism, 63P
 Binding affinity, 534P
 Binding assays, 170P
 Binding sites, 117P
 Binding studies, 376P
 Biovideograph, 586P, 588P, 591P
 Biphasic relaxation, 71P
 Bladder, mouse, 85P
 Blood clotting, 700P
 Blood loss, 460P
 Blood pressure, 128P, 130P, 249P, 318P, 319P, 385P, 387P, 586P
 Body temperature, 507P
 Bombesin, 412P, 567P
 Brain, dialysis, 194P
 Brain, human, 273P
 Brain, rat, 117P, 401P
 Breast milk, 482P
 Bremazocine, 47P, 558P
 (³H)-bremazocine binding, 656P
 BRL 16644, duration of action, 154P
 BRL 20627, 568P, 569P
 Bronchial hyperreactivity, 241P
 Bronchioles, 709P
 Bronchoconstriction, 340P
 Bronchospasm, 439P
 Bucindolol, 536P
 Bumetanide, 697P
 Buprenorphine, 276P, 715P
 Bupropion, 540P
 Butoxamine, 620P
 BW755C, 220P, 611P

 Cadmium, 137P, 705P
 Caffeine, 369P, 470P, 555P, 631P
 Calcitonin, 255P, 518P
 Calcium, 331P, 378P, 468P, 537P, 611P, 631P, 708P
 Calcium activated potassium permeability, 546P
 Calcium antagonists, 32P, 36P, 81P, 174P, 208P, 209P, 210P, 389P, 390P, 454P, 469P, 612P, 613P, 685P
 Calcium channel antagonists, 80P, 330P
 Calcium channels, 80P, 81P, 421P, 454P, 469P, 502P, 505P
 Calcium entry blockade, 133P, 134P, 475P, 480P
 Calcium entry blockers, 333P, 556P, 614P
 Calcium influx, 239P
 Calcium ions, 330P
 Calcium paradox, 123P
⁴⁵Calcium uptake, 685P
 Cannabinoids, 634P
 Capsaicin, 644P
 Captopril, 321P, 476P
 Carbachol, 192P, 470P
 Carbohydrate absorption, 65P
 β-Carbolines, 433P, 630P, 649P
 Carbon dioxide, 342P
 Carbon fibre electrodes, 172P
 Cardiac automaticity, 506P
 Cardiac injury, 123P
 Cardiac muscle, 333P
 Cardiac stimulant, 124P, 125P
 Cardiac supersensitivity, 383P
 Cardioplegia, 32P
 Cardiovascular control, conscious rat, 132P
 Cardiovascular effects, 139P, 140P
 Cardiovascular pharmacology, 368P, 583P
 Carotid body, rabbit, 430P
 Carprofen, 55P
 Carrageenin, 354P
 Cascade superfusion, 404P
 Catecholamines, 23P, 402P, 632P
 Caudate nucleus, rabbit, 16P
 Caudate nucleus, rat, 472P
 Cell accumulation, 350P
 Cell proliferation, 595P
 Central cardiovascular control, 132P
 Central muscle relaxant, 1P, 2P
 Central/peripheral mechanisms, 135P
 Cerebellum, 189P, 277P
 Cerebellum, rat, 407P
 Cerebral cortex, 67P
 Cerebral cortex, rat, 12P, 107P, 108P, 468P, 542P
 Cerebrospinal fluid, 264P
 CGS 8216, 95P
 Channel block, 457P
 Chemical sympathectomy, 682P
 Chemotactic activity, 359P
 Chick biventer muscle, 501P
 Chlordiazepoxide, 265P, 637P
 2-Chloroadenosine dependence, 368P
 2-Chlorobenzylidene malononitrile, 495P
 (³H)-N-(chloroethyl) norapomorphine binding, 547P

p-Chlorophenylalanine, 626P
 Cholinergic antagonists, 559P
 Cholinergic neurones, 573P
 Cholinergic responses, 568P
 Cholinergic transmission, 70P
 Choroid plexus, 627P
 Chromans, 154P
 Ciclazindol, 400P
 Cimetidine, 59P, 448P, 485P
 Cinnamyl anthranilate, 447P
 Cinnarizine, 205P
 Cirazoline, 299P, 300P, 305P
 Circadian variation, 46P
 Citalopram, 411P, 718P
 Clobazam, 484P, 487P
 Clonidine, 3P, 74P, 97P, 106P, 305P, 463P, 562P, 640P, 652P
 Clonidine binding, 26P
 Clonidine withdrawal, 135P
 Clorgyline, 571P
 Clorgyline resistant amine oxidase, 301P, 302P, 303P
 Clozapine, 409P
 Cocaine, 462P
 Cockroach, CNS, 432P
 Collagen, 182P
 Colon, human, 144P, 604P
 Colon, rabbit, 145P
 Computers, 185P, 583P, 589P, 592P
 Conjugation, 63P
 Convulsants, 285P, 294P
 Convulsions, 76P
 Coronary casodilator mediator, 382P
 Corpus striatum, 244P
 Corpus striatum, rat, 103P, 193P
 Cortex, chick, 606P
 Cortex, rat, 109P, 115P, 149P
 Cortical neurones, 116P, 190P
 Cortico-striatal pathway, 6P
 Corticotrophin releasing factor, 435P
 Corwin, 459P
 Covalent binding, 373P
 CRAO, 671P
 CRF-41, 436P
 CS₂, 75P
 Curve fitting program, 582P
 Curve stripping, 714P
 Cutaneous response, 486P
 Cyanide, 326P
 Cyclic voltammetry, 632P
 Cyclo-oxygenase, 515P
 Cyclo-oxygenase inhibition, 52P
 Cyclo-oxygenase products, 496P
 Cytisine, 272P
 Cytochrome P450, 448P, 499P
 Cytoplasmic calcium, 351P
 Cytotoxic-induced vomiting, 490P
 DBA/2 mice, 405P
 De-esterification, 324P
 Defence reaction, 317P
 Delayed hypersensitivity, 417P
 Dental pain, 489P
 Depression, 57P, 670P
 Descending inhibitory systems, 188P
 Desensitization, 216P
 Desmethylinipramine, 310P, 638P
 Dexamethasone, 380P
 Dextran, 243P
 Diazepam, 22P, 114P, 487P
 Diabetes, 161P, 248P, 249P, 366P, 660P
 Dibenzoxazepine, 169P
 Dietary fat, 701P
 Difenacoum, 338P
 Diflunisal, 349P
 Digoxin, inotropic drugs, 120P
 Dihydroalprenolol binding, 629P
 5,6-Dihydroxy-2-dipropylaminotetralin, 138P
 1,1-dimethyl-4-phenylpiperazinium, 144P
 Dipyrindamole, 376P, 381P, 625P
 Diquat, 691P
 Dissociation, 288P
 Distribution, 167P
 Dithiothreitol, 322P
 Diuretics, 332P, 481P
 Divalent cations, 66P, 224P
 DNA-binding, 345P
 DOCA/Saline hypertensive rats, 131P, 575P
 Domperidone, 430P, 687P
 (³H)-Domperidone, 545P
 Dopamine, 7P, 8P, 10P, 17P, 98P, 100P, 104P, 246P, 315P, 416P, 512P, 541P, 548P, 645P, 647P, 719P
 Dopamine agonists, 30P, 101P, 127P, 139P, 196P, 410P
 Dopamine antagonists, 101P
 Dopamine containing neurones, 258P
 Dopamine- β -hydroxylase, 75P
 Dopamine metabolites, 429P
 Dopamine receptors, 16P, 70P, 105P, 193P, 271P, 398P, 409P, 420P, 426P, 427P, 430P, 544P, 545P, 636P, 655P, 676P
 Dopamine D₂ receptors, 7P
 Dopamine receptors, brain, 102P
 Dopamine receptors, peripheral, 138P
 Dopamine release, 4P, 194P, 292P, 538P
 Dopamine supersensitivity, 269P
 Dopamine turnover, 264P
 Dothiepin, 638P
 Down regulation, 297P
 Doxepin, 564P
 Drug absorption, 165P
 Drug-induced relaxation, 363P
 Drug metabolism, 166P, 167P, 168P
 Drug receptor interactions, 422P
 Drug transfer, 482P
 DS 103-282, 1P, 2P
 Dye, 494P
 Dye binding, 581P

Dynorphin fragments, 170P
 Eicosanoids, 446P
 Electroconvulsive shock, 114P, 263P, 372P, 566P, 574P
 Electroencephalogram, 266P, 289P, 652P
 Electrophysiology, 423P
 Enalapril, 323P, 324P
 Encainide, 126P
 Endometrium, guinea-pig, 713P
 β -Endorphin, 493P
 Endothelia, 334P, 445P
 Endotoxin, 346P
 Enkephalin, 199P
 Enkephalin, D-Ala²-D-Leu⁵-, effect on vasoactive intestinal peptide-induced secretion in rat small intestine, 371P
 Enkephalin, Met-, 262P
 Enkephalin, (D-Pen², L-Pen⁵), 669P
 Enprofylline, 710P
 Enzyme release, 350P
 Enzyme solubilisation, 303P
 Epilepsy, 355P, 433P, 484P
 Epileptic brain damage, 284P
 Ergot alkaloids, 196P
 Erythrocyte-encapsulation, 336P
 Erythrocytes, chicken, 686P
 Erythrosine, B, 206P
 Ethanol, 245P, 118P, 245P, 485P, 499P, 639P, 660P, 701P
 Ethanol dependence, 538P
 Ethanol tolerance, 537P, 663P
 Ethanolamine O-sulphate, 431P
 17 α -Ethinylloestradiol, 63P
 Ethnic differences in metabolism, 488P
 7-Ethoxycoumarin, 580P
 Ethylenediamine, 62P, 268P
 Ethylketocyclazocine, effect on vasoactive intestinal peptide-induced secretion in rat small intestine, 371P
 N-ethylmaleimide, 664P
 Ethinylloestradiol, 563P
 Etorphine, 48P
 Excitatory amino acid receptors, 525P
 Excitatory amino acids, 201P, 401P
 Exploratory behaviour, 95P, 449P, 455P
 Extravasation, 180P
 Facilitation, 509P
 Fatty acids, 677P
 Fear, 110P
 Fenfluramine, 91P, 233P
 Fentanyl, 500P
 Fibrin, 240P
 Field stimulation, 71P, 144P, 175P
 Fistula, 177P
 FK 33-824, effect on secretory phase of vasoactive intestinal peptide response in rat small intestine, 371P
 Flufenamic acid, 349P
 Fluid models, 593P
 Fluid transport, 73P
 Fluidising alcohols, 52P
 Flupenthixol, 99P
 Fluphenazine decanoate, 17P
 FPL 22712, 218P
 FPL 52694, 177P
 Folate, 289P, 627P
 Food intake, 396P, 550P, 662P
 Forskolin, 259P, 576P
 Free radicals, 628P
 Frontal cortex, mouse, 146P
 Gastric acid secretion, 177P, 178P, 565P
 Gastric cyclo-oxygenase, 353P
 Gastric emptying, 119P
 Gastric motility, 478P, 569P
 Gastric pressure, 689P
 Gastric secretion, 78P, 581P
 Gastric ulceration, 691P
 Germfree rats, 64P, 329P
 Glaucoma, 587P
 Globus palidus, 666P
 Glipizide, 166P
 Glucocorticoids, 597P
 Glutamate, 15P, 18P, 407P, 543P
 L-glutamic acid, 202P
 Glutathione, 321P
 Glycine, 19P
 Glycosine-hydrolase inhibitor, 65P
 Graft rejection, 222P
 Grooming behaviour, 412P
 Guanosine 3'5' monophosphate, cyclic, 355P, 407P
 H77, 253P
 Haemodynamics, 127P, 299P, 316P
 Haemoglobin, 129P
 Haemophilus influenzae, 241P
 Haemorrhage, 255P, 262P
 Half-life, 551P, 552P
 Haloperidol, 409P, 561P
 Head twitches, 13P
 Heart rate, 135P, 385P
 Heart, dog, 124P, 126P
 Heart, guinea-pig, 30P, 120P, 123P, 218P
 Heart, human, 72P
 Heart, rat, 27P, 304P, 382P
 Hepatic portal vein, 208P
Helix aspersa, 100P
 Hexamethonium, 457P
 High pressure liquid chromatography, 429P, 527P
 Hippocampal pathways, 18P
 Hippocampal theta rhythm, 104P
 Hippocampus, 202P
 Hippocampus, rat, 641P, 668P
 Histamine, 145P, 241P, 243P, 282P, 478P,

601P, 606P
 Histamine antagonists, 371P, 384P
 Histamine receptors, 414P, 200P
 Histamine H₁-receptors, 200P, 437P, 438P, 711P
 Histamine H₂ receptors, 437P, 438P
 Histamine release, 162P, 242P, 374P
 Histamine secretion, 58P
 D-homo-corticosteroid, 595P
 Hydrochlorothiazide, 38P
 6-Hydroxydopamine, 383P
 3-(3-hydroxy-phenyl)-N-n-propylpiperidine, 646P, 676P
 5-Hydroxytryptamine, 13P, 82P, 83P, 84P, 85P, 90P, 92P, 96P, 132P, 133P, 178P, 192P, 263P, 265P, 291P, 292P, 298P, 308P, 394P, 466P, 511P, 512P, 514P, 518P, 523P, 535P, 539P, 541P, 570P, 626P, 642P, 649P, 668P, 674P, 719P
 (3H)-5-hydroxytryptamine, 131P
 5-Hydroxytryptamine agonists, 667P, 676P
 5-Hydroxytryptamine antagonists, 68P, 607P
 5-Hydroxytryptamine autoreceptor, 673P
 5-Hydroxytryptamine receptors, 83P, 107P, 273P, 297P, 607P, 651P, 667P
 5-Hydroxytryptamine ₂ receptors, 295P, 296P
 5-Hydroxytryptamine "D" receptors, 295P, 296P
 5-Hydroxytryptamine release, 513P, 718P
 5-Hydroxytryptamine uptake, 68P, 197P, 198P, 406P, 411P, 451P, 453P, 673P
 5-Hydroxytryptophan, 92P
 Hyperpolarisation, 35P
 Hyperpyrexia, 577P
 Hypertension, 50P, 137P, 251P, 483P, 702P
 Hypertensive rat, 441P, 474P
 Hyperpyrexia, 564P
 Hyperthermia, 233P
 Hypoxia, 226P, 706P
 Hypotension, 24P
 Hypothalamus, rat, 257P, 513P, 545P, 718P
 Hypothermia, 254P, 574P

 Ibuprofen, 716P
 Ibopamide, 127P
 ICI 154129, 144P
 IgE, 243P
 Ileum, rat, 308P
 Ileum, guinea-pig, 176P, 257P
 Imipramine, 406P, 668P
 (3H)-imipramine binding, 57P, 198P, 451P, 453P, 664P
 Immunology, 56P
 In vivo binding, 194P
 Indolamines, 92P
 Indolamines, brain, 14P
 Indomethacin, 343P, 444P, 446P, 496P
 Infection, 220P
 Infendolol, 491P
 Inferior eyelid, 155P
 Inflammation, 56P, 240P, 444P
 Inhalation, 169P, 494P
 Inhibition, 168P, 689P
 Inhibitory nerve stimulation, 363P
 Innovation, 584P
 Inositol phospholipids, 468P
 Inotropic agent, 30P
 Insulin, 25P, 366P, 660P
 Interactions, 20P, 21P
 Intestinal absorption, 64P, 306P
 Intestinal perfusion, 65P
 Intestinal secretion, rat, 74P
 Intestinal transport, 443P
 Intestine, rat, 165P 307P
 Intraatrial injection, 399P
 m-Iodobenzylguanidine, 707P
 Ion channel inhibitors, 33P, 86P
 Ion channels, 174P
 Ion transport, 609P, 697P
 Irritant receptors, 217P
 Ischaemia, 362F, 519P
 3-Isobutyl-1-methylxanthine, 576P
 Isoguvacine, 88P, 89P
 Isoprenaline, 576P, 629P

 Jejunum, rat, 73P
 Kainate, 289P
 Kallikrein, renal, 690P
 Keratinocytes, cultured human, 375P
 Ketamine, 173P, 703P
 Ketanserin, 273P, 295P, 575P, 608P
 Ketoprofen, 553P
 Kidney, 497P
 Kidney, rabbit, 37P
 Kidney, rat, 38P, 250P
 Kinetic analysis, 8P
 Kinetic modelling, 696P
 Kinetics, 337P, 345P

 Laboratory class instruction, 591P
 Lacrimal gland, 67P
 Lactate, 209P
 Lanthanum, 181P
 Lead, 39P, 199P
 Learning, 287P
 Leptazol, 266P
 Leukocytes, human, 596P
 Leukotrienes, 153P, 215P, 217P, 218P, 358P, 598P
 Lidocaine, 203P
 κ-Ligand, 275P
 Ligand binding, 81P, 314P, 665P
 Light stimulation, 261P

Lignocaine, 579P
 Lipid solubility, 410P
 Lipids, 25P
 Lipophilicity, 534P
 Liposomes, 522P, 691P
 Lipoxxygenase, 446P, 515P
 Lipoxxygenase inhibition, 611P
 Lipoxxygenase metabolites, 445P
 Lithium, 91P, 200P, 394P, 443P, 554P, 555P
 Liver blood flow, 320P, 682P
 Liver disease, 579P
 Liver microsomes, human, 580P
 Locomotor activity, 416P, 424P
 Locomotor hyperactivity, 98P
 Locus coeruleus, 3P, 423P
 Locust muscle, 524P
 Locust nerve cord, 525P
 Longitudinal myometrium, 467P
 Loop-diuretics, 697P
 Lorazepam, 530P
 Lung dysfunction, 419P
 Lung, guinea-pig, 179P, 357P, 358P, 520P
 Lung, human, 72P
 Lung membranes, 605P
 Lung, piglet, 223P
 Lung, rat, 219P, 453P
 Lung tone, 496P
 LY141865, 139P
 Lymphocytes, 240P, 595P
 Lyon hypertensive rats, 25P
 Lysergic acid diethylamide, 82P
¹²⁵I-lysergic acid diethylamide, 83P

 M₁ and M₂ receptors, 69P
 Macrocortin, 597P
 Macrophage oxidative burst, 343P
 Magnesium, 481P, 695P, 698P
 Magnesium exchange, 696P
 Mast cells, 58P, 162P, 374P, 601P, 674P
 Mazindol, 148P
 MD260355, 210P
 MDL 722222, 466P
 Mecamylamine, 9P
 Medullary neurones, 452P
 Megakaryocytes, 361P
 Membrane lipids, 537P
 Membrane potentials, 325P
 Membrane stabilization, 184P
 Memory, 287P, 530P
 Mepacrine, 380P
 Meptazinol, 121P, 678P
 Meptazinol, antinociception, 559P
 (³H)-mepyramine binding, 661P
 6-Mercaptopurine, 492P
 Mesenteric arteries, 234P, 528P
 Mesenteric vessels, 302P
 Metabolism, 563P
 Methemoglobin, 326P
 Methergoline, 9P
 Methohexitone, 87P, 211P, 703P
 Methotrexate, 522P, 691P
 5-Methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl) 1H indole succinate see RU 24969
 p-Methoxybenzoic acid, 212P
 p-Methoxycinnamic acid, 212P
 8-Methoxypsoralen, 167P
 5-Methoxytryptamine, 718P
 N-methyl-D-aspartic acid, 202P
 Methyl β-carboline-3-carboxylate, 77P
 α-Methyl noradrenaline, 562P
 Methylphenidate, 93P
 Methylxanthines, 179P, 471P
 Methysergide, 608P
 Metoclopramide, 119P, 490P, 504P, 568P
 Metoprolol, 362P
 Metyrapone, 499P
 Mianserin, 429P
 Mianserin enantiomers, 228P, 651P
 Microautoradiography, 497P
 Microcomputers, 185P, 186P, 424P
 Microelectrophoresis, 190P
 Microiontophoresis, 191P, 282P, 529P
 Microsomal enzyme induction, 447P
 Microsomes, 61P, 621P
 Microspheres, 458P
 Mini-pig skin, 163P
 Mitochondria, 621P, 680P, 705P, 708P
 Mixed lymphocyte reaction, 492P
 Monoamine oxidase, 302P, 304P, 621P, 623P, 671P
 Monoamine oxidase inhibitors, 20P, 21P, 564P, 577P, 624P
 Monoamine uptake inhibitors, 154P
 Monohydroxy-eicosatetraenoic acids, 359P
 Morphine, 48P, 188P, 245P, 500P
 Morphine cue recognition, 276P
 Motor behaviour, 105P, 549P
 MR 2034, effect on vasoactive intestinal peptide-induced secretion in rat small intestine, 371P
 Mucociliary transport, 693P, 694P
 Mucolytics, 694P
 Mucosal membrane potential, 35P
 Multiple choice questions, 590P
 Muscarinic acetylcholine receptors, 67P, 108P, 284P, 422P, 678P
 Muscarinic agonists, 66P
 Muscarinic antagonists, 370P
 Muscimol, 88P
 Mutagenicity, 169P
 Mutagenesis, 61P
 Mutant mice, 189P
 Myenteric neurones, 422P
 Myocardial infarction, 698P
 Myocardial infarction, 716P
 Myocardial ischaemia, 29P, 200P, 381P
 Myocardium, 67P

Myoclonus, 648P, 667P
Myocytes, rat isolated, 304P
Myometrium, human, 53P
Myorelaxant, 332P

NADPH, 349P
Nafazatrom, 237P
Naloxone, 142P, 293P, 558P
Nasal cavity pressure, 300P
Naturalistic stimulation, 247P
Nematode infection, 626P
Neomycin, 35P
Nephrotoxicity, 335P
Nerve conduction, 364P
Neuroblastoma cells, 523P
Neurohypophysis, 262P
Neuroleptics, 17P, 98P, 246P, 399P
514P, 534P, 544P, 636P
Neuromuscular blocking agents, 613P
Neuromuscular junction, 252P, 470P,
500P, 703P, 704P
Neuromuscular junction, chick, 87P,
171P, 211P, 365P
Neuronal receptor antagonists, 466P,
511P
Neurotensin, 4P, 413P, 531P, 533P,
657P
Neurotoxin ethylcholine mustard aziri-
dinium ion, 573P
Neurotransmitter, 404P
Neurotransmitter release, 663P
New chemical entities, 584P
Nicardine, 556P
Nicotine, 9P, 117P, 270P, 272P, 315P
Nifedipine, 476P, 503P, 556P
Nitrendipine, 80P, 502P
Nitrobenzylthioinosine, 625P
Nomifensine, 472P
Non-adrenergic non-cholinergic nerves,
238P
Non-opiate antinociception, 560P
Non-steroidal anti-inflammatory drugs,
599P
Noradrenaline, 3P, 43P, 116P, 245P,
260P, 541P, 542P, 638P, 702P
Noradrenaline overflow, 309P
Noradrenaline receptors, 405P
(³H)-noradrenaline release, 685P
Noradrenaline release, non-synchronous,
224P
Noradrenergic transmission, 683P
Norapomorphine, 5P
Normetazocine homologues, 274P
Nucleus accumbens, 393P
Nucleus accumbens, rat, 641P
Nucleus tractus solitarius, 192P
Nucleoside transport, 625P

Obesity, rats, 540P
Oestradiol, 688P

17 β -Oestradiol, 661P
Oestrogen, 229P, 371P, 677P
Oestrogen conjugates, 699P
Oestrone sulphate, 64P
Oestrous cycle, 219P
Olfactory bulbectomy, 670P
Olfactory cortex, 112P, 643P
Ontogeny, 199P
Ontogeny, behaviour, 635P
Opiate antagonists, 142P, 143P, 559P,
666P
 δ -opiate antagonists, 529P
Opiate antinociception, 560P, 561P
 δ -Opiate binding site, 669P
Opiate receptors, 46P, 414P, 423P, 654P,
715P, 717P
 δ -Opiate receptors, 48P, 143P
 κ opiate receptor, 47P, 656P
 μ -Opiate receptor, 276P
Opiates, 23P, 224P, 255P, 434P, 633P,
650P
Opioid binding, 274P, 274P
Opioid peptides, 642P
Opioids, 328P, 529P, 657P
Orientation, 344P
Ouabain, 506P, 517P
Oxidative phosphorylation, 705P
Oxypertine, 11P, 269P, 455P
Oxytoxin, 633P

pA₂, 136P
PAF-acether *see* Platelet activating
factor
Pain sensitivity, 46P
Palmitate, 219P
Palmityl-lysophosphatidate, 341P
Pancreatic islets, rat, 207P
Papillary muscle, guinea-pig, 239P
Paracetamol, 488P
Paracetamol metabolism, 485P
Parameter estimation, 714P
PDE inhibitors, 125P
Pelvic nerve stimulation 145P
Pemoline, 93P
D-penicillamine, 550P
Pentylentetrazole, 22P, 286P, 450P
Peptide levels, brain, 99P
Perforant path, 18P
Pergolide, 260P, 316P
Periaqueductal grey, 531P
Peripheral tissues, 370P
Permixon, 327P
Pharmacokinetics, 114P, 166P,
338P, 339P, 490P, 589P, 593P
Pharmacological assays, 170P
Phenylbiguanide, 298P, 570P
 β -Phenylethylamine, 293P, 391P, 624P
 β -Phenylethylamine, 294P
Phenobarbitone, 320P, 682P
Phenoxybenzamine, 40P, 408P

Phentolamine, 149P
 8-Phenyltheophylline, 368P
 Phosphatidylinositol, 108P, 200P, 214P, 401P
 Phospholipase, 118P, 380P
 Phospholipase, A₂, 597P
 Photoaffinity, 461P
 Photodynamic effects, 206P
 Physico-chemical properties, 482P
 Picrotoxin, 286P, 648P
 (³H)-piflutixol, 655P
 Pinacidil, 621P
 Pirofenolol, 210P, 389P, 390P
 Piribedil, 392P
 Pituitary, rat, 290P
 Plasma, 161P, 554P
 Plasma catecholamines, 232P
 Platelet activating factor, 179P, 180P, 239P, 341P, 351P, 377P, 439P, 468P
 Platelet activation, 214P, 600P
 Platelet aggregation, 159P, 160P, 181P, 182P, 183P, 184P, 221P, 360P, 439P, 701P
 Platelets, 156P, 157P, 158P, 160P, 313P, 325P, 342P, 347P, 356P, 377P, 442P, 664P
 Platelets, human, 57P, 82P, 351P, 460P, 521P
 Platelets, rabbit, 229P, 352P
 Platelets, rat, 352P
 Pleurisy, 55P, 354P, 516P
 Polymyxin, B, 171P, 365P
 Portal vein, 332P, 378P, 684P
 Post mortem brain, 267P
 Post natal thyroid deficiency, 244P
 Post partum guinea-pigs, 467P
 Potassium-evoked contractures, 610P
 Prazosin, 45P, 236P, 578P
 (³H)-prazosin, 156P
 Prednisolone, 444P
 Preganglionic sympathetic nerve activity, 608P
 Pregnenolone-16 α carbonitrile, 479P
 Prejunctional modulators, 456P
 Prenalterol, 459P
 Pressor response, 317P
 Priflurolol, 203P
 Procaine, 498P
 Procatenolol, 24P
 Progesterone, 14P
 Prolactin, 548P, 687P, 688P
 Prolactin release, 259P
 Proline endopeptidase, 413P
 Promethazine anticholinergic metabolites, 395P
 Propranolol, 59P, 111P, 618P, 629P
 (³H)-N,n-propylnorapomorphine binding, 408P
 Prostacyclin, 29P, 31P, 164P, 216P, 222P, 223P, 237P, 352P, 442P, 598P, 700P
 Prostacyclin analogues, 160P
 Prostacyclin receptors, 216P
 Prostaglandin D₂, 49P, 162P
 Prostaglandin E₁, 352P, 442P
 Prostaglandin E₁, 6-oxo-, synthesis, 51P
 Prostaglandin E₂, 343P, 441P
 Prostaglandin F₂, 6-keto, 353P
 Prostaglandin biosynthesis, 361P
 Prostaglandin 'reciprocal coupling factor', 54P
 Prostaglandin release, 163P, 711P
 Prostaglandins, 50P, 53P, 234P, 387P, 603P
 Prostanoids, 356P, 565P, 602P
 Prostatic hyperplasia, 327P
 Proxicromil, 165P
 Psoriasis, 359P
 Puerperal depression, 493P
 Pulmonary anaphylaxis, 49P
 Pulmonary artery, 309P
 Pulmonary function, 217P
 Pulmonary metabolism, 213P
 Pulmonary responses, 346P
 Pulse interval, 319P
 Purification, 367P
 Purinergic receptors, 223P
 Purines, 150P
 Putrescine, 348P
 Pyridostigmine, 252P
 Quercetin, 515P
 Quinacrine, 623P
 Quinazolines, 388P
 Quinolinic acid, 115P
 Quinoxalines, 345P
 Quipazine, 96P
 Radical scavengers, 373P
 Radioligands, 231P, 461P
 Radioligand assay, 370P
 Radioligand binding, 582P
 Ranitidine, 282P, 284P
 Rauwolscine, 42P, 314P
 Reactive intermediate, 373P
 Receptor binding, 66P, 136P, 201P
 Receptor regulation, 513P
 Receptors, 344P
 Receptors, presynaptic, 41P, 45P
 Reciprocal coupling factor, 161P
 Rectococcygeus muscle, rabbit, 70P
 Reflex responses, 84P
 Renal blood flow, 37P
 Renal clearance, 695P
 Renal cortex, rat, 322P
 Renal failure, 337P
 Renal hypertensive rats, 575P
 Renal nerve, 250P
 Renin, 39P
 Renin-angiotensin system, 250P, 253P

Renin inhibitors, 253P
 Reperfusion, 122P, 628P
 Reperfusion arrhythmias, 33P, 237P, 519P
 Reperfusion model, 716P
 Reserpine, 91P, 450P, 619P
 Respiration, 84P, 586P
 Respiratory neurones, 191P
 Retina, carp, 646P
 Retina, rabbit, 261P
 Retinoids, 56P, 516P
 Retractor penis muscle, bovine, 226P
 RO 5-4864, 76P, 280P
 Ro 11-1430, 56P
 Ro 15-1788, 288P
 Ro 31-1118, 152P, 183P, 235P
 Rotation, 416P, 420P
 Rotational behaviour, 271P
 RS-51324, 386P
 RU24969, 675P
⁸⁶Rubidium efflux, 207P
 Rutin, 515P
 RB781094, 128P, 129P, 130P, 474P
 RX7781094 analogues, 311P, 312P
 (³H)-RX 781094, 109P
 RX 783006, effect on secretory phase of vasoactive intestinal peptide response in rat small intestine, 371P

 Salbutamol, 670P
 Salicylates, 489P, 602P
 Saralasin, 251P
 Schizophrenia, 11P
 Sea-anemone toxin, 367P
 Sedation, 76P, 572P
 Seizures, 279P
 Selectivity, 42P
 β_1 -selectivity, 459P
 Semen, 554P
 Seminal vesicle, 465P, 681P
 Sensitization-IgE antibodies, 605P
 Sensory ganglia, 674P
 Septal driving, 104P
 Sexual excitement, 392P
 Sgd 101/74, 155P
 Shock, 142P
 Signal acquisition, 186P
 Simulation, 589P, 592P
 Sinus node, 389P, 390P
 SKF 38393, 428P
 SK&F 93319, 438P
 Skeletal muscle, frog, 588P
 Slide demonstration, 587P
 Slow potentials, 270P
 Slow-release formulation, 551P, 552P
 Small airway, human, 709P
 Smoke, 494P
 Smooth muscles, 174P, 421P, 614P
 Smooth muscle contraction, 227P

 Social behaviour, mouse, 634P
 Sodium, 38P
 Sodium, potassium-adenosine triphosphatase, 517P
 Sodium channels, 204P
 Sodium cromoglycate, 497P
 Sodium deficiency, 323P
 Sodium transport, 204P
 Soleus muscle, 631P
 Solubilization, 102P, 469P
 Soman, 25-P
 Somatostatin, 689P
 Species differences, 129P
 Sperm motility, 555P
 Spleen, rat, 404P
 Spinal cord, 644P
 Spinal cord, cat, 1P, 2P
 Spinal cord, frog, 281P
 Spinal cord, rat, 28P, 115P
 Spiperone, 5P
 (³H)-spiperone, 655P
 (³H)-spiperone binding, 102P, 103P, 408P
 Spontaneously hypertensive rats, 26P, 27P, 28P, 141P, 316P
 SRS-A, 418P
 Substance P agonists, 415P
 Stereoselectivity, 138P
 Stereotyped behaviour, 293P, 428P, 473P
 Steroid conjugates, 306P
 Stomach strips, 175P
 Stream, 328P
 Striatum, human, 7P
 Striatum, pig, 427P
 Striatum, rat, 4P, 5P, 15P, 90P, 292P, 403P, 420P, 427P, 538P, 547P, 639P, 648P, 717P
 Subcellular fractionation, 198P
 Sub-chronic tolerance, 557P
 Substance P, 79P, 257P, 258P, 415P, 571P
 Substance P agonists, 571P
 Substance P antagonist, 79P
 Substance P antibody, 258P
 Substance P receptor, 79P
 Substantia nigra, rat, 101P, 271P, 426P, 719P
 Sulphasalazine, 604P
 Sulphonylureas, 207P
 Sulpiride, 100P
 (³H)-sulpiride binding, 427P
 Superior cervical ganglion, rat, 68P, 173P, 571P
 Superior mesenteric artery, 320P, 615P
 Supersensitivity, 16P, 254P, 514P, 548P, 619P
 Surface charge, 36P
 Sympathetic activity, 318P
 Sympathetic neuroeffector junction, 616P

Sympathetic transmission, 456P
Synaptic membranes, 413P, 543P
Synaptosomes, 8P, 111P

Tachykinins, 415P
Taenia coli, guinea-pig, 206P
Tail artery, rat, 230P, 649P
Tamoxifen, 688P
Tardive dyskinesias, 269P
Target size analysis, 454P
Taurine, 19P, 279P
(³H)-taurine, 261P
Taurocholic acid, 337P
Teaching, 590P, 591P
Temperature, 32P
Terbutaline, 710P
Tetanic fade, 86P
Tetracycline, 365P
Tetrahydronaphthalene derivatives, 645P
4,5,6,7-Tetrahydroisoxazolo(5,4-c)
pyridin-3-ol(THIP), 283P, 574P
Tetrodotoxin, 364P
Thalamus, rat, 105P, 650P
Theophylline, 710P
THEOS, 197P
Thermodynamics, 344P
Thermogenesis, 397P, 400P
Thio-disulphide interchange, 321P
Thrombin, 341P
Thromboxane A₂, 213P, 214P, 215P, 357P,
358P, 360P, 600P
Thromboxane B₂, 213P, 221P, 440P
Thromboxane A₂ agonists, 603P
Thromboxane metabolite, 49P
Thromboxane receptors, 378P
Thromboxane synthetase inhibition, 341P,
347P,
Thromboxanes, 159P, 604P, 700P
Thymocytes, rat, 609P
Thyroid deficiency, 103P
Thyroid status, 106P
Thyroid hormones, 566P
Thyrotropin releasing hormone, 97P,
263P, 533P, 539P, 641P, 657P, 687P
Tiapride, 398P
Timoprazole, 419P
(³H)-tiotidine binding, 679P
TL99, 140P
Tocainide, 579P
α-Tocopherol, 684P, 706P
Tolerance, 22P, 245P
Toxin, 367P
Trachea, guinea-pig, 503P
Transmethylation, 242P
Tranlycypromine, 564P, 577P
Trifluoperazine, 473P
Trimethoquinol, 600P
Tropine benzoate analogs, 511P
Tryptamine, 13P, 451P, 535P, 649P
Tryptamine uptake, 12P

Tryptophan, 13P, 14P
TSH, 566P
Tuberculum olfactorium, 717P
Tubocurarine, 86P, 546P
Turpentine inflammation, 54P
Tyramine, 301P

U-46619, 53P
UK-36,327, 124P, 125P
UK 37,248, 356P
Ulcers, 602P
Ultrastructural enzyme histochemistry,
303P
Uptake blocker, 462P
Urethane, 270P
Uterus, rabbit, 229P
Uterus, rat, 208P, 371P

Vagal stimulation, 478P
Vagus nerve, rat isolated, 298P
Vas deferens, human, 683P
Vas deferens, mouse, 146P, 147P, 245P,
456P, 679P, 683P
Vas deferens, rabbit, 149P, 275P
Vas deferens, rat, 148P, 331P, 464P,,
504P, 505P, 510P, 654P
Vascular endothelium, 180P
Vascular permeability, 711P
Vascular reactivity, 164P
Vascular smooth muscle, 333P, 334P, 508P
Vasoactive intestinal protein, 259P,
Vasoconstriction, 69P, 134P, 230P, 334P,
458, 476P, 477P, 480P, 508P, 509P,
528P
Vasodilation, 441P, 477P
Vasodilators, 34P, 612P
Vecuronium, 613P
Ventral globus pallidus, 393P
Ventricular dysrhythmias, 232P
Verapamil, 36P, 181P, 205P, 210P, 331P,
379P, 381P, 502P, 551P, 552P, 609P,
684P
Vitamin K, 339P
Voltammetry, 172P, 195P, 647P

Warfarin, 338P
Water deprivation, 391P
Water intake, 662P
Whole blood, 347P
Withdrawal syndrome, 26P, 558P, 618P,
640P
WY 26392, 462P, 463P
Wy 26703, 147P, 463P

Yohimbine, 195P, 310P, 396P, 578P

Zetidine, 426P
Zinc, 137P
ZK36374, 31P